{"id":55602,"date":"2023-04-06T18:06:31","date_gmt":"2023-04-06T16:06:31","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/beasley-allen-ashcraft-gerel-law-firms-talc-mdl-leadership-rejects-johnson-johnsons-second-attempt-to-abuse-bankruptcy-process\/"},"modified":"2023-04-06T18:06:31","modified_gmt":"2023-04-06T16:06:31","slug":"beasley-allen-ashcraft-gerel-law-firms-talc-mdl-leadership-rejects-johnson-johnsons-second-attempt-to-abuse-bankruptcy-process","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/beasley-allen-ashcraft-gerel-law-firms-talc-mdl-leadership-rejects-johnson-johnsons-second-attempt-to-abuse-bankruptcy-process\/","title":{"rendered":"Beasley Allen\/Ashcraft &amp; Gerel Law Firms: Talc MDL Leadership Rejects Johnson &amp; Johnson\u2019s Second Attempt to Abuse Bankruptcy Process"},"content":{"rendered":"<div>\n<p>TRENTON, N.J.&#8211;(BUSINESS WIRE)&#8211;This week, Johnson &amp; Johnson announced what the company says is a resolution of tens of thousands of talc ovarian cancer and mesothelioma claims.<\/p>\n<p>\nThe following statement is a reaction from attorneys <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.beasleyallen.com%2Fattorney%2Fleigh-odell%2F&amp;esheet=53376232&amp;newsitemid=20230406005508&amp;lan=en-US&amp;anchor=Leigh+O%26%238217%3BDell&amp;index=1&amp;md5=fffe52f36e8a29619b6bd617e5138ec7\" rel=\"nofollow noopener\" shape=\"rect\">Leigh O\u2019Dell<\/a> of the Beasley Allen Law Firm and <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.ashcraftandgerel.com%2Four-attorneys%2Fmichelle-a-parfitt%2F&amp;esheet=53376232&amp;newsitemid=20230406005508&amp;lan=en-US&amp;anchor=Michelle+Parfitt&amp;index=2&amp;md5=e2c3e72fe4888b208165237817442f88\" rel=\"nofollow noopener\" shape=\"rect\">Michelle Parfitt<\/a> of Ashcraft &amp; Gerel, co-chairs of the plaintiffs\u2019 steering committee in the federal court multidistrict litigation of these cases:<\/p>\n<p>\n<i>J&amp;J\u2019s arrogance is boundless, and its mockery of the court system demonstrates a callous, bullying mindset. There are no tactics too underhanded for the company to use to try to avoid paying reasonable compensation to these cancer victims.<\/i><\/p>\n<p>\n<i>The talc \u201csettlement\u201d being touted by J&amp;J and the media is NOT a settlement. It is an illusory proposal for a bankruptcy plan, yet another attempt by J&amp;J to misuse the bankruptcy system. All 14 members of the plaintiffs\u2019 steering committee reject this proposal.<\/i><\/p>\n<p>\n<i>In fact, the terms are considerably worse than a proposal that we and other firms representing ovarian cancer victims rejected last June, at a time when it appeared that all plaintiffs could be stuck in bankruptcy court for years. Since then, the Third Circuit Court of Appeals set aside J&amp;J\u2019s bankruptcy and our negotiating position significantly improved.<\/i><\/p>\n<p>\n<i>The settlement that J&amp;J is now trying to impose on plaintiffs, with the aid of a small number of firms handling talc cases, includes:<\/i><\/p>\n<ul class=\"bwlistdisc\">\n<li>\n<i>all current and future ovarian cancer victims<\/i><\/li>\n<li>\n<i>all current and future mesothelioma victims<\/i><\/li>\n<li>\n<i>all attorney general actions for all states, and<\/i><\/li>\n<li>\n<i>all other talc-related claims, including claims by medical cost insurers against J&amp;J.<\/i><\/li>\n<\/ul>\n<p>\n<i>While J&amp;J\u2019s proposed $8.9 billion offer sounds like a lot of money, it is not enough when you consider the terms of the proposal. This settlement proposal would pay far less than $120,000 per case, if that.<\/i><\/p>\n<p>\n<i>The costs of medical care and lost wages alone for ovarian cancer victims approach $500,000. That does not address the pain and suffering nor punitive damages those women and their families have suffered by J&amp;J\u2019s massive and deliberate cover-up of the dangers of its asbestos-laden talc products.<\/i><\/p>\n<p>\n<i>Rest assured, we are vigorously opposing this deal and will continue fighting to get fair compensation for clients. And through a remarkable team effort, we are confident that this ploy by J&amp;J to unfairly force a bad deal will be rebuffed, and we will be able to negotiate a fair one for clients. Alternatively, we will get this second bankruptcy thrown out, just as we did the first, so that we can present clients\u2019 cases before juries again soon.<\/i><\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\nMark Annick<br \/>\n<br \/>800.559.4534<br \/>\n<br \/><a target=\"_blank\" href=\"&#109;&#97;&#x69;l&#116;&#x6f;&#x3a;m&#97;&#x72;&#x6b;&#64;&#97;&#x6e;d&#114;&#x6f;&#x76;e&#116;&#x74;&#x2e;c&#111;&#x6d;\" rel=\"nofollow noopener\" shape=\"rect\">&#x6d;&#x61;&#114;k&#x40;&#x61;&#110;&#100;r&#x6f;&#x76;&#101;&#116;t&#x2e;&#x63;&#111;m<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>TRENTON, N.J.&#8211;(BUSINESS WIRE)&#8211;This week, Johnson &amp; Johnson announced what the company says is a resolution of tens of thousands of talc ovarian cancer and mesothelioma claims. The following statement is a reaction from attorneys Leigh O\u2019Dell of the Beasley Allen Law Firm and Michelle Parfitt of Ashcraft &amp; Gerel, co-chairs of the plaintiffs\u2019 steering committee &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/beasley-allen-ashcraft-gerel-law-firms-talc-mdl-leadership-rejects-johnson-johnsons-second-attempt-to-abuse-bankruptcy-process\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-55602","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Beasley Allen\/Ashcraft &amp; Gerel Law Firms: Talc MDL Leadership Rejects Johnson &amp; Johnson\u2019s Second Attempt to Abuse Bankruptcy Process - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/beasley-allen-ashcraft-gerel-law-firms-talc-mdl-leadership-rejects-johnson-johnsons-second-attempt-to-abuse-bankruptcy-process\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Beasley Allen\/Ashcraft &amp; Gerel Law Firms: Talc MDL Leadership Rejects Johnson &amp; Johnson\u2019s Second Attempt to Abuse Bankruptcy Process - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"TRENTON, N.J.&#8211;(BUSINESS WIRE)&#8211;This week, Johnson &amp; Johnson announced what the company says is a resolution of tens of thousands of talc ovarian cancer and mesothelioma claims. The following statement is a reaction from attorneys Leigh O\u2019Dell of the Beasley Allen Law Firm and Michelle Parfitt of Ashcraft &amp; Gerel, co-chairs of the plaintiffs\u2019 steering committee ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/beasley-allen-ashcraft-gerel-law-firms-talc-mdl-leadership-rejects-johnson-johnsons-second-attempt-to-abuse-bankruptcy-process\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-06T16:06:31+00:00\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/beasley-allen-ashcraft-gerel-law-firms-talc-mdl-leadership-rejects-johnson-johnsons-second-attempt-to-abuse-bankruptcy-process\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/beasley-allen-ashcraft-gerel-law-firms-talc-mdl-leadership-rejects-johnson-johnsons-second-attempt-to-abuse-bankruptcy-process\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Beasley Allen\\\/Ashcraft &amp; Gerel Law Firms: Talc MDL Leadership Rejects Johnson &amp; Johnson\u2019s Second Attempt to Abuse Bankruptcy Process\",\"datePublished\":\"2023-04-06T16:06:31+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/beasley-allen-ashcraft-gerel-law-firms-talc-mdl-leadership-rejects-johnson-johnsons-second-attempt-to-abuse-bankruptcy-process\\\/\"},\"wordCount\":473,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/beasley-allen-ashcraft-gerel-law-firms-talc-mdl-leadership-rejects-johnson-johnsons-second-attempt-to-abuse-bankruptcy-process\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/beasley-allen-ashcraft-gerel-law-firms-talc-mdl-leadership-rejects-johnson-johnsons-second-attempt-to-abuse-bankruptcy-process\\\/\",\"name\":\"Beasley Allen\\\/Ashcraft &amp; Gerel Law Firms: Talc MDL Leadership Rejects Johnson &amp; Johnson\u2019s Second Attempt to Abuse Bankruptcy Process - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"datePublished\":\"2023-04-06T16:06:31+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/beasley-allen-ashcraft-gerel-law-firms-talc-mdl-leadership-rejects-johnson-johnsons-second-attempt-to-abuse-bankruptcy-process\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/beasley-allen-ashcraft-gerel-law-firms-talc-mdl-leadership-rejects-johnson-johnsons-second-attempt-to-abuse-bankruptcy-process\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/beasley-allen-ashcraft-gerel-law-firms-talc-mdl-leadership-rejects-johnson-johnsons-second-attempt-to-abuse-bankruptcy-process\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Beasley Allen\\\/Ashcraft &amp; Gerel Law Firms: Talc MDL Leadership Rejects Johnson &amp; Johnson\u2019s Second Attempt to Abuse Bankruptcy Process\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Beasley Allen\/Ashcraft &amp; Gerel Law Firms: Talc MDL Leadership Rejects Johnson &amp; Johnson\u2019s Second Attempt to Abuse Bankruptcy Process - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/beasley-allen-ashcraft-gerel-law-firms-talc-mdl-leadership-rejects-johnson-johnsons-second-attempt-to-abuse-bankruptcy-process\/","og_locale":"en_US","og_type":"article","og_title":"Beasley Allen\/Ashcraft &amp; Gerel Law Firms: Talc MDL Leadership Rejects Johnson &amp; Johnson\u2019s Second Attempt to Abuse Bankruptcy Process - Pharma Trend","og_description":"TRENTON, N.J.&#8211;(BUSINESS WIRE)&#8211;This week, Johnson &amp; Johnson announced what the company says is a resolution of tens of thousands of talc ovarian cancer and mesothelioma claims. The following statement is a reaction from attorneys Leigh O\u2019Dell of the Beasley Allen Law Firm and Michelle Parfitt of Ashcraft &amp; Gerel, co-chairs of the plaintiffs\u2019 steering committee ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/beasley-allen-ashcraft-gerel-law-firms-talc-mdl-leadership-rejects-johnson-johnsons-second-attempt-to-abuse-bankruptcy-process\/","og_site_name":"Pharma Trend","article_published_time":"2023-04-06T16:06:31+00:00","author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/beasley-allen-ashcraft-gerel-law-firms-talc-mdl-leadership-rejects-johnson-johnsons-second-attempt-to-abuse-bankruptcy-process\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/beasley-allen-ashcraft-gerel-law-firms-talc-mdl-leadership-rejects-johnson-johnsons-second-attempt-to-abuse-bankruptcy-process\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Beasley Allen\/Ashcraft &amp; Gerel Law Firms: Talc MDL Leadership Rejects Johnson &amp; Johnson\u2019s Second Attempt to Abuse Bankruptcy Process","datePublished":"2023-04-06T16:06:31+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/beasley-allen-ashcraft-gerel-law-firms-talc-mdl-leadership-rejects-johnson-johnsons-second-attempt-to-abuse-bankruptcy-process\/"},"wordCount":473,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/beasley-allen-ashcraft-gerel-law-firms-talc-mdl-leadership-rejects-johnson-johnsons-second-attempt-to-abuse-bankruptcy-process\/","url":"https:\/\/pharma-trend.com\/en\/beasley-allen-ashcraft-gerel-law-firms-talc-mdl-leadership-rejects-johnson-johnsons-second-attempt-to-abuse-bankruptcy-process\/","name":"Beasley Allen\/Ashcraft &amp; Gerel Law Firms: Talc MDL Leadership Rejects Johnson &amp; Johnson\u2019s Second Attempt to Abuse Bankruptcy Process - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"datePublished":"2023-04-06T16:06:31+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/beasley-allen-ashcraft-gerel-law-firms-talc-mdl-leadership-rejects-johnson-johnsons-second-attempt-to-abuse-bankruptcy-process\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/beasley-allen-ashcraft-gerel-law-firms-talc-mdl-leadership-rejects-johnson-johnsons-second-attempt-to-abuse-bankruptcy-process\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/beasley-allen-ashcraft-gerel-law-firms-talc-mdl-leadership-rejects-johnson-johnsons-second-attempt-to-abuse-bankruptcy-process\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Beasley Allen\/Ashcraft &amp; Gerel Law Firms: Talc MDL Leadership Rejects Johnson &amp; Johnson\u2019s Second Attempt to Abuse Bankruptcy Process"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/55602","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=55602"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/55602\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=55602"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=55602"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=55602"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}